SCHEMBL6805953

SCHEMBL6805953

O=C(Nc1cncn(C(C(=O)O)c2cccc(Br)c2)c1=O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GPR35 Q9HC97 1/20 0.40
KDM4D Q6B0I6 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ABL1 P00519 1/20 0.38
TSHR P16473 1/20 0.38
RIN1 Q13671 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HIF1A Q16665 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.37
GRIK1 P39086 1/20 0.37
CA12 O43570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805321 0.89 IDO1 (0.47) IDO1TDO2MAPTALDH1A1KDM4D
SCHEMBL6805622 0.88 IDO1 (0.43) IDO1TDO2MAPTALDH1A1GPR35
SCHEMBL6804869 0.84 POLB (0.50) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL6802997 0.82 RAB9A (0.47) IDO1TDO2MAPTALDH1A1KDM4D
SCHEMBL6803439 0.82 ALDH1A1 (0.47) IDO1TDO2MAPTALDH1A1KDM4D
SCHEMBL6805808 0.82 SMN1; SMN2 (0.47) IDO1TDO2MAPTALDH1A1KDM4D
SCHEMBL6804846 0.82 GPR132 (0.47) ALDH1A1MEN1KMT2ATSHRGAA
SCHEMBL6810352 0.80 NPC1 (0.47) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL6799314 0.79 RAB9A (0.49) MAPTALDH1A1MEN1KMT2ATDP1
SCHEMBL6810211 0.79 ALDH1A1 (0.36) IDO1TDO2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US claimed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP claimed
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same ONO PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063936-A1 Pyrimidine derivatives and process for preparing the same DPYD, NUDT1, UMPS IDO1 932/4885TDO2 2114/4885MAPT 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.